Fig_4.tif (1.82 MB)

Specificities mediating neutralization breadth and potency in the top 42 Protocol C neutralizers.

Download (0 kB)
posted on 28.01.2016 by Elise Landais, Xiayu Huang, Colin Havenar-Daughton, Ben Murrell, Matt A. Price, Lalinda Wickramasinghe, Alejandra Ramos, Charoan B. Bian, Melissa Simek, Susan Allen, Etienne Karita, William Kilembe, Shabir Lakhi, Mubiana Inambao, Anatoli Kamali, Eduard J. Sanders, Omu Anzala, Vinodh Edward, Linda-Gail Bekker, Jianming Tang, Jill Gilmour, Sergei L. Kosakovsky-Pond, Pham Phung, Terri Wrin, Shane Crotty, Adam Godzik, Pascal Poignard

(A) Samples are ranked by their neutralization score on the 37-virus panel (37vP) (S4 Fig in S1 Text and S2 Table in S1 Text). VC: Visit Code (months post infection). Symbols recapitulate the strength of the phenotypes tested using the different approaches detailed in this manuscript (S7-S11 Figures in S1 Text) to determine the Env epitope region targeted by the plasma broadly neutralizing activity: gp120 absorption of bnAb activity, effect of b6 competition in gp120 absorption experiments, RSC3 binding and neutralization competition, HIV-2 chimera neutralization, viruses produced in presence of kifunensine or bearing mutations. Absent (-), very weak (+/-), weak (+), moderate (++), strong (+++), phenotype was attributed based on i) the median fold or average percent decrease in ID50 and ii) the fraction of viruses which neutralization ID50 was decreased <2 fold, <10 <50 fold or <20%, <40%, <60%, <80%. Blank = not tested, NB: not binding. A dominant specificity was attributed for each sample based on results from all these experiments. UD: Undefined. (B) Overall distribution of dominant nAb specificities mediating plasma neutralization breadth in the top 42 Protocol C neutralizers as detailed in (A).